eCite Digital Repository

Topical application of hyaluronic acid-RGD peptide-coated gelatin/epigallocatechin-3 gallate (EGCG) nanoparticles inhibits corneal neovascularization via inhibition of VEGF production

Citation

Miyagawa, T and Chen, Z-Y and Chang, C-Y and Chen, K-H and Wang, Y-K and Liu, G-S and Tseng, C-L, Topical application of hyaluronic acid-RGD peptide-coated gelatin/epigallocatechin-3 gallate (EGCG) nanoparticles inhibits corneal neovascularization via inhibition of VEGF production, Pharmaceutics, 12, (5) Article E404. ISSN 1999-4923 (2020) [Refereed Article]


Preview
PDF
2Mb
  

Copyright Statement

2020 by the authors. Licensee MDPI, Basel, Switzerland. Licensed under Creative Commons Attribution 4.0 International (CC BY 4.0) http://creativecommons.org/licenses/by/4.0/

DOI: doi:10.3390/pharmaceutics12050404

Abstract

Neovascularization (NV) of the cornea disrupts vision which leads to blindness. Investigation of antiangiogenic, slow-release and biocompatible approaches for treating corneal NV is of great importance. We designed an eye drop formulation containing gelatin/epigallocatechin-3-gallate (EGCG) nanoparticles (NPs) for targeted therapy in corneal NV. Gelatin-EGCG self-assembled NPs with hyaluronic acid (HA) coating on its surface (named GEH) and hyaluronic acid conjugated with arginine-glycine-aspartic acid (RGD) (GEH-RGD) were synthesized. Human umbilical vein endothelial cells (HUVECs) were used to evaluate the antiangiogenic effect of GEH-RGD NPs in vitro. Moreover, a mouse model of chemical corneal cauterization was employed to evaluate the antiangiogenic effects of GEH-RGD NPs in vivo. GEH-RGD NP treatment significantly reduced endothelial cell tube formation and inhibited metalloproteinase (MMP)-2 and MMP-9 activity in HUVECs in vitro. Topical application of GEH-RGD NPs (once daily for a week) significantly attenuated the formation of pathological vessels in the mouse cornea after chemical cauterization. Reduction in both vascular endothelial growth factor (VEGF) and MMP-9 protein in the GEH-RGD NP-treated cauterized corneas was observed. These results confirm the molecular mechanism of the antiangiogenic effect of GEH-RGD NPs in suppressing pathological corneal NV.

Item Details

Item Type:Refereed Article
Keywords:RGD peptide, anti-angiogenesis, corneal neovascularization (NV), epigallocatechin gallate (EGCG), eye drops, gelatin, hyaluronic acid (HA), nanoparticles, drug delivery
Research Division:Biomedical and Clinical Sciences
Research Group:Medical biotechnology
Research Field:Gene and molecular therapy
Objective Division:Expanding Knowledge
Objective Group:Expanding knowledge
Objective Field:Expanding knowledge in the environmental sciences
UTAS Author:Liu, G-S (Associate Professor Guei-Sheung Liu)
ID Code:139225
Year Published:2020
Web of Science® Times Cited:4
Deposited By:Menzies Institute for Medical Research
Deposited On:2020-06-02
Last Modified:2021-03-24
Downloads:1 View Download Statistics

Repository Staff Only: item control page